Global Mncs & Local Giants: Winning in India
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Avenue Supermarts Limited AVEU.BO, DMART in Value Retailer at Premium Multiples; Initiate with Price: Rs664.40 Neutral Price Target: Rs635.00
Completed 07 Apr 2017 04:07 AM HKT Disseminated 07 Apr 2017 04:44 AM HKT Asia Pacific Equity Research 07 April 2017 Initiation Neutral Avenue Supermarts Limited AVEU.BO, DMART IN Value Retailer at Premium Multiples; Initiate with Price: Rs664.40 Neutral Price Target: Rs635.00 We initiate on Avenue Supermarts (ASL) with a Neutral rating and Mar-18 price India target of Rs635. ASL (operates stores under D-Mart brand), with a strong Consumer, Retail, Media execution track record, is a quality play on the Indian F&G retail sector in our AC opinion, being the fastest-growing and most profitable retailer. We forecast Latika Chopra, CFA 27%/34% revenue/EPS CAGR over FY17-20. However, significant gains post the (91-22) 6157-3584 [email protected] listing (120% above the offer price) lead to current valuations of 55x/42x Bloomberg JPMA CHOPRA <GO> FY18E/19E P/E, which fairly reflect the long-term growth opportunity in our J.P. Morgan India Private Limited view. Any minor lapse near term (store opening, comps, and/or margins) and Ebru Sener Kurumlu substantial investments in E-Commerce (earnings dilutive) could strain valuation (852) 2800-8521 multiples. [email protected] Much to like here. Food retailing is about format and execution and in our J.P. Morgan Securities (Asia Pacific) Limited view ASL has been able to achieve this combination well. We like ASL’s execution capabilities, single format focus, best-in-class productivity metrics Price Performance (sales densities ~2-3x peers), prudent store expansion strategy and strong focus 650 on customer satisfaction partly aided by its ‘everyday low price’ positioning. -
First Call 22Mar21
India Equity Research March 22, 2021 FIRST CALL DAILY REPORT MARKETS Change in % Metals & Mining - Sector Update - Tangshan cuts may push up steel prices 21-Mar-21 1D 1M 1Y Media reports suggest local authorities in Tangshan have imposed a fresh set of Nifty 50 14,558 -1.1 -2.8 76.2 Nifty 200 7,583 -1.2 -2.6 76.7 production curbs on steel value chain until end-CY21 in order to reduce air pollution. Nifty 500 12,174 -1.2 -2.1 78.8 According to Mysteel consultancy, if the draft plan is adopted, pig iron production and iron ore demand would fall by 22mt and 35mt, respectively. Taken together with INDIA STOCK PERFORMANCE the possibility of export rebate cuts, we believe exports from China can reduce significantly, thereby supporting steel prices. 16,000 80,000 14,500 70,000 Dabur India - Company Update - Growing naturally 13,000 (x) 11,500 60,000 (x) We recently met Mr. Mohit Malhotra, CEO of Dabur India, to gain insights into the 10,000 50,000 company’s growth plans, product launches and strategy to counter competition, 8,500 7,000 40,000 among others. Highlights: i) The pandemic has brought in new consumers to the health portfolio. ii) The worst is behind for fruit juices and other segments squeezed Nifty Index MSCI EM Index - Local Currency (RHS) by the lockdown. iii) Strong focus on innovation (recent launches in PET bottle juices, health drops, health juices, Amla-plus juices, pickles and apple cider vinegar are all doing well). GLOBAL 21-Mar-21 1D 1M 1Y Avenue Supermarts - Company Update - Time to whet appetite for online Dow 32,862 -0.5 4.3 63.6 While DMart has taken incremental steps to ramp up online grocery, it still seems to China 3,432 -0.9 -7.1 27.0 be on the sidelines and contemplating its merit. -
SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI Trading As ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP
Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SANJEEVAK 1586083 01/08/2007 MANOJ ANANT JOSHI trading as ;AKSHAY PHARMA REMEDIES KAVRANA HOUSE, OPP. COTTON GREEN RLY. STN. MUMBAI-400033. MANUFACTURE & MERCHANT INDIAN NATIONAL Used Since :31/01/2001 MUMBAI MEDICINAL PREPARATIONS. 537 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 SEPTIGARD 1741718 08/10/2008 INDERJIT SINGH trading as ;INDERJIT SINGH B-104 , SWASTHYA SINGH , NEW DELHI -92 MERCHANTS & MANUFACTUERERS Address for service in India/Agents address: MAHTTA & CO. 43 - B/3, MAHTTA HOUSE,UDHAM SINGH NAGAR, LUDHIANA - 141 001, (PUNJAB). Proposed to be Used DELHI MEDICINAL & PHARMACEUTICAL PREPARATIONS. 538 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 FAIR & BEAUTY 1803779 08/04/2009 GALPHA LABORATORIES LIMITED 221, Kanakia Zillion, E Wing Bandra Kurla Complex Annex LBS Marg & CST Road Junction Kurla West MUMBAI 400070 MANUFACTURERS AND MERCHANTS INDIAN NATIONAL Used Since :15/11/2007 MUMBAI PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES 539 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 O-BAMA 1815900 08/05/2009 KREMOINT PHARMA PVT. LTD. 151/5, SHRI KRISHNA DARSHAN, GARODIA NAGAR, GHATKOPAR (E), BOMBAY-400 077. MANUFACTURERS AND MERCHANTS. A CORPORATE ENTITY INCORPORATED IN INDIA UNDER THE COMPANIES ACT 1956. Address for service in India/Attorney address: KRISLAW CONSULTANTS BUILDING NO.4, C/104, SHANKESHWAR PALMS, BEHIND MODEL SCHOOL, KUMBHARKHANPADA, SUBHASH ROAD, DOMBIVILI(W) 421202 Used Since :02/05/2009 MUMBAI PHARMACETICAL AND MEDICINAL PREPARATIONS. 540 Trade Marks Journal No: 1836 , 12/02/2018 Class 5 AYUSHAKTI D-VYRO 1815928 08/05/2009 SMITA NARAM BUNGALOW NO.31, NEXT TO M. -
Grant Thornton Bharat's Report on Integrated Reporting in India
Integrated reporting in India Survey on adoption and way forward December 2020 Contents Forewords 03 Grant Thornton Bharat survey on integrated reporting – key findings 05 Overview of integrated reporting 08 Benefits for organisations 12 Global landscape 16 Evolving scenario in India 21 Path to success 28 Way forward 32 02 Integrated reporting in India Foreword - Grant Thornton Bharat The ongoing pandemic has reinforced my belief that inclusive growth is more important to shape a #VibrantBharat than any other priority. Indian businesses must step up to this challenge as catalysts of employment, technological advancement and innovation. Since the new Companies Act 2013, India has made recognise the exceptional work done by individuals significant progress in corporate reporting and and organisations in India towards sustainable disclosures. I believe this decade will see similar progress development goals (SDGs). Our firm works extensively on integrated reporting, as it is an opportunity to not with such stakeholders to build social capital, address only differentiate yourself but to contribute to shaping a gender inequalities, protect the environment for future more vibrant Indian economy. generations and achieve the shared purpose of helping shape our #VibrantBharat. Almost 70% of those surveyed believe that integrated reporting will help them enhance stakeholder value, Vishesh C. Chandiok while the consensus seems to be that greater awareness CEO and clearer guidelines will pave the way for more Grant Thornton Bharat companies to adopt integrated reporting in India. I am delighted that this report is being released at the Grant Thornton Bharat SABERA Awards 2020 that Integrated reporting in India 0 3 Foreword - IIRC With intangible assets now making up 90% of market value in the S&P 500, businesses need to show their stakeholders that they create value and report on not just financial capitals but also intellectual, environmental, manufactured and human capitals. -
Consumer Goods Recovery in Discretionary and Urban Sales Led to Better Q3 Sector Update
Consumer Goods Recovery in discretionary and urban sales led to better Q3 Sector Update Consumer goods companies’ Q3 performance was driven by sales recovery of Q3FY2021 Results Review discretionary categories (such as value-added hair oil and personal care products), sustained higher demand for healthcare and hygiene products, better traction to Sector: Consumer Goods new launches, and higher demand in rural markets coupled with improving demand in urban markets. General trade continues to grow strongly, e-commerce mix to Sector View: Positive overall revenue is improving due to higher sales and modern trade channel has witnessed sequential improvement due to recovery in urban sales. Most consumer goods companies under our coverage registered organic revenue growth of 6%-16%, driven by domestic volume growth of 7%-18% in Q3. Paint companies, including Asian Paints, registered strong volume growth of 30%, led by sustained high demand in tier III/IV towns and improving demand in metros and top cities due to receding scare of virus and improving construction and real estate activities. Overall, Sharekhan’s consumer goods universe registered revenue growth of ~14% in Q3FY2021, better than 9.1% growth achieved in Q2FY2021. Significant increase Our coverage universe in prices of palm oil, copra, other edible oils, and raw tea/coffee resulted in gross Companies CMP Reco. PT margin decline for companies such as HUL, Godrej Consumer Products (GCPL), (Rs) (Rs) Marico, and Tata Consumer Products (TCPL). However, lower ad spends and cost- Asian Paints 2,389 Buy 3,000 saving initiatives arrested the sharp decline of 80-100 bps in operating profit margins (OPM) for some companies. -
Management Discussion and Analysis
Marico Limited Integrated Report 2018-19 Management Discussion and Analysis 7KLVGLVFXVVLRQFRYHUVWKHƬQDQFLDOUHVXOWVDQGRWKHU 7KHJRYHUQPHQWIHOOPDUJLQDOO\VKRUWRILWVƬVFDOGHƬFLW GHYHORSPHQWVIRUWKH\HDUHQGHG0DUFKLQUHVSHFW WDUJHWIRU)<WKHGHƬFLWƬQDOO\HTXDOLQJRI*'3 RI0DULFR&RQVROLGDWHGFRPSULVLQJLWVGRPHVWLFDQG FRPSDUHGWRWDUJHW7KHFHQWUDOJRYHUQPHQWKDVSXW LQWHUQDWLRQDOEXVLQHVV7KH&RQVROLGDWHGHQWLW\KDVEHHQ ƬVFDOFRQVROLGDWLRQRQKROGLQ)<E\WDUJHWLQJDGHƬFLW UHIHUUHGWRDVo0DULFRpRUo*URXSpRUo&RPSDQ\pLQ HTXDOWRRI*'3FORVHWRWKH)<RXWFRPHDQGKLJKHU WKLVGLVFXVVLRQ WKDQWKHHDUOLHUWDUJHWRIRI*'3 6RPHVWDWHPHQWVLQWKLVGLVFXVVLRQGHVFULELQJSURMHFWLRQV 7KH,QGLDQUXSHHGHSUHFLDWHGE\DJDLQVWWKH86GROODU HVWLPDWHVH[SHFWDWLRQVRURXWORRNPD\EHIRUZDUG UHƮHFWLQJWKHZLGHQLQJFXUUHQWDFFRXQWGHƬFLWDQGWHSLG ORRNLQJ$FWXDOUHVXOWVPD\KRZHYHUGLƪHUPDWHULDOO\ IRUHLJQLQYHVWPHQWƮRZV,WGHSUHFLDWHGE\DERXWLQ IURPWKRVHVWDWHGRQDFFRXQWRIYDULRXVIDFWRUVVXFKDV UHDOHƪHFWLYHWHUPV)RUH[UHVHUYHKROGLQJVGHFOLQHGE\ FKDQJHVLQJRYHUQPHQWUHJXODWLRQVWD[UHJLPHVHFRQRPLF |%LOOLRQWR%LOOLRQLQ)< GHYHORSPHQWVH[FKDQJHUDWHDQGLQWHUHVWUDWHPRYHPHQWV +HDGOLQHUHWDLOLQƮDWLRQDYHUDJHGWKHORZHVWVLQFHD DPRQJRWKHUPDFURHFRQRPLFIDFWRUVFRPSHWLWLYH QHZPHWULFZDVLQWURGXFHGLQ0XFKRIWKHGHFOLQHFDQ HQYLURQPHQWSURGXFWGHPDQGDQGVXSSO\FRQVWUDLQWVZLWKLQ EHH[SODLQHGE\PXWHGIRRGSULFHVZKLFKRFFXS\RIWKH ,QGLDDQGWKHFRXQWULHVZLWKLQZKLFKWKH*URXSFRQGXFWVLWV FRQVXPHUSULFHEDVNHWDVWKHLUDYHUDJHDQQXDOLQFUHDVHLQ EXVLQHVV )<ZDVRQO\%\FRQWUDVWFRUHLQƮDWLRQUHPDLQHG HOHYDWHGDWRQSULFHLQFUHDVHVIRUKRXVLQJHGXFDWLRQ Update on Macro Economic DQGUHFUHDWLRQVHUYLFHVDQGKHDOWKFDUH)XHOLQƮDWLRQDOVR -
Hy Sun Missed the Pharma Rally: the Answer Is Hidden in a Bet Many Failed — Speciality Drugs - the Economic Times
12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets News Industry RISE Politics Wealth MF Tech Jobs Opinion NRI Panache ET NOW More Aayush English Edition | E-Paper Tech Consumer Markets Corporate Governance Telecom + OTT Auto + Aviation Pharma Fintech + BFSI Economy Infra Environment Energy Business News › Prime › Pharma › Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Getty Images MARKETS hy Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs Dilip Shanghvi, founder and managing director, Sun Pharmaceuticals Synopsis Sun Pharma is the only Indian company to have made some inroads into speciality drugs. What worries investors is high investments and uncertainties over ramp up in revenue. The stock can still see upside because of its current valuations, strong India business, and any positive surprises in US generic business. But it is crucial that its speciality bet pays off. BACK TO TOP https://economictimes.indiatimes.com/prime/pharma-and-healthcare/why-sun-missed-the-pharma-rally-the-answer-is-hidden-in-a-bet-many-failed-spe… 1/11 12/3/2020 Sun Pharma: Why Sun missed the pharma rally: the answer is hidden in a bet many failed — speciality drugs - The Economic Times Home ETPrime Markets NeCwasllI nitd uas trbyleRssISiEngP oilniti cdsisWgeuailthse fMoFr tTheceh InJodbisanOpinion NRI Panache ET NOW More pharmaceutical industry. The stocks of pharma companies have been on a tear since the beginning of the Covid-19 crisis. -
Pharmaceuticals Stellar Quarter; Healthy Outlook Sector Update
Pharmaceuticals Stellar quarter; Healthy Outlook Sector Update Q2FY2021 was yet another stellar quarter for pharmaceutical companies under Q2FY2021 Results Review Sharekhan’s pharma universe. The quarter witnessed a sustained improvement in Sector: Pharmaceuticals the US business while the domestic business showed signs of improvement. The overall plant utilization levels during Q2FY2021 were at normal levels (as against Sector View: Positive relatively low utilization levels in previous quarter), thus yielding costs benefits. For the quarter, the pharma companies delivered revenue growth of 8.8% y-o-y, while sequentially as well it clocked a growth of 8.3%. Topline performance was better than estimates and was driven by sturdy performance of the US business, while the India operations also grew a decent pace. Growth in the base business, stabilizing price erosion and new launches led to the growth in US business, while in India business, companies with a relatively higher share of chronic business grew strongly and outperformed the industry. Select players such as Aurobindo, Cadila and Cipla reported strong 12.5%, 18% and 10% y-o-y growth respectively in the US business. Divis labs also reported a strong 21% y-o-y growth in the topline backed by a strong performance in the API segment, while Laurus labs posted a 60% revenue Our active coverage universe growth on the back of an impressive growth in the formulations segment. Operating CMP PT profit for the universe increased sharply by 21% y-o-y. Operating margin also Companies Reco. (Rs) (Rs) expanded by 251 bps y-o-y, better the expected 150 bps y-o-y expansion. -
Saturday, 23Rd August 2014 Index Levels : Market Trend (Nifty)
` Saturday, 23rd August 2014 Index Levels : Market Trend (Nifty): Trend Reversal Point INDEX SUPPORTS RESISTANCES Period Current Trend (TRP)Nifty close basis NIFTY# 7930/8000/8090 Short Term Trend UP DOWN BELOW 7750 (7913.20) 7850/7760 SENSEX# 26250/26000 26550/26700/27200 Medium Term UP DOWN BELOW 7650 (26419.55) ITE-35* -------- -------- Long Term Trend UP DOWN BELOW 6500 (10239.68) ND #as on 22 August 2014 Imtiaz Merchant’s Best Picks: Indices: CURRENT Domestic COMPANY NAME SIZE SECTOR Close Points % Chg PRICE Indices Large Cipla Health Care 499 BSE Sensex 26419.55 59.44 0.23 % Cap Large Industrials and UPL 338 Nifty 7913.20 22.10 0.28 % Cap Capital Goods ITE Shariah 10239.68 42.83 0.42 % 35* S&P CNX 500 1919.15 4.92 0.12 % Note: (Buying should be done from a medium to long term perspective) Shariah Advance/ Advance Decline AD Un- Market Brief Decline Ratio Changed BSE 1462 1572 0.93:1 114 On the back of positive global cues and some NSE 693 782 0.89:1 60 reform announcements by the Union Shariah Government, the markets on Friday ended the Universe*** 291 269 1.08:1 15 day and the week on positive note; Auto, Info. Technology and Health Care sectors were the flavor of the week. The undertone appears to Global Indices Close Points % Chg be bullish. All the trends are up. More reform Dow Jones* 16979.13 60.36 0.36% announcements from the Govt. and good NASDAQ* 4526.48 5.62 0.12% corporate results will further fuel the rally and FTSE* 6755.48 22.18 0.33% the Nifty is likely to see the 8000 level soon. -
Management Discussion & Analysis
MANAGEMENT DISCUSSION Marico’s portfolio of products, has, over the services that are safe and scientific. The current AND ANALYSIS years, created enduring value for its consumers. In structure of the skin care services industry is the process, it has consolidated its presence in fragmented with local brands catering to local In line with international practice, Marico has Skin Care, Oral Care, Health and Hygiene the market. In all its key categories of coconut needs. There are very few corporate service been reporting consolidated results taking into Products, Hair Care, Coconut Oil, Refined Edible oils, hair oils, anti-lice treatment, fabric care and providers. Marico’s Kaya Skin Clinics attempt to fill account the results of its subsidiaries. This Oils, Foods and Beverages, Dairy Products, premium refined edible oils, Marico has built this need gap with US FDA approved cosmetic Discussion therefore covers the financial results etc. The FMCG industry is one of the largest significant market shares. During FY04, Marico dermatological procedures that enhance the and other developments during April ’03 - March ’04 in India, with an annual estimated turnover of has kept pace with the momentum of growth quality, look and feel of Indian skin. (FY04) in respect of Marico Consolidated - Marico Rs. 480,000 million. achieved in the past couple of years, with Industries Limited together with its subsidiaries double-digit growth in topline and bottomline. OPPORTUNITIES Marico Bangladesh Limited (MBL), MBL Industries MARICO IS COMMITTED TO AND THREATS Limited (MBLIL), Kaya Skin Care Limited (KSCL) IMPROVING THE QUALITY OF Marico’s presence overseas (comprising Your Company continuously seeks new and its joint venture, Sundari LLC (Sundari) and PEOPLE’S LIVES THROUGH exports from India and local operations in a foreign opportunities in expanding its current portfolio of Sundari Spa LLC. -
Stewart Investors Global Emerging Markets Sustainability Leaders Fund (DST)
Stewart Investors Global Emerging Markets Sustainability Leaders Fund (DST) Quarterly Investment Report 1 April - 30 June 2021 Q 2 Contents Portfolio Performance 3 Portfolio Allocation and Stock Holdings 4 Largest Stock Holdings 5 Market Capitalisation Allocation 5 Significant Transactions 6 Contribution Analysis 6 Performance Analysis 7 Sector Performance 7 Full Portfolio Listing 8 Important Information 9 STEWART INVESTORS GLOBAL EMERGING MARKETS SUSTAINABILITY LEADERS FUND (DST) - QUARTERLY 2 INVESTMENT REPORT 30 JUNE 2021 Portfolio Performance 30 June 2021 Fund Details Investment Objective Fund Managers: Jack Nelson/David Gait The fund's investment objective is to achieve long-term capital growth by investing US$263.3 in large and mid-capitalization equities in emerging economies, including those Fund Size: companies listed on developed market exchanges whose activities predominantly take place in emerging market countries. Number of Holdings: 45 Cumulative Performance to June 30 2021 Since 10 7 5 3 2 1 6 3 % Change: Inception* Years Years Years Years Years Year Months Months Portfolio Return (Net) 61.9 - - - - - 40.4 5.9 7.1 Benchmark Return ** 67.1 - - - - - 41.4 7.6 5.1 Annualised Performance to 30 June 2021 Since Inception 31 Mar 2020 10 yrs 5 yrs 3 yrs Portfolio Return (Net) 47.1 - - - Benchmark Return 50.8 - - - * The inception date for performance measurement purposes is 31 March 2020. Returns are cumulative, net of fees and gross of tax, and denominated in USD. ** The benchmark for the Stewart Investors Global Emerging Markets Sustainability Leaders Fund (DST) is the MSCI Emerging Markets Index and is calculated gross of tax. Please note that past performance is not a reliable indicator of future returns. -
ICICI Securities – Retail Equity Research Result Update Marico
Marico (MARLIM) CMP: | 546 Target: | 630 (15%) Target Period: 12 months BUY August 1, 2021 Saffola growth momentum continues… About the stock: Marico is one of the major FMCG companies present in hair oil, edible oil, foods & personal care segment. Major brands include Parachute, Saffola, Nihar, Hair & Care, Set Wet, Livon and Beardo. Particulars The company has an overall distribution network of more than 5 million Particulars (| crore) Amount outlets and direct reach of ~1 million outlets. Through its stockist network, Market Capitalization 70,503.0 it reaches 58000 villages Total Debt (FY21) 340.0 Cash and Investments (FY21) 1,572.0 Update Result With the high gross margins of ~47%, Marico is able to spend 10% of its EV 69,271.0 sales for advertisements to support new categories & products 52 week H/L (|) 552 / 333 Equity capital 129.0 Face value (|) 1.0 Q1FY22 Results: Marico reported robust revenue growth in Q1FY22 results. Shareholding pattern Sales were up 31.2% YoY with strong volume recovery and price hikes (in %) Sep-20 Dec-20 Mar-21 Jun-21 EBITDA was at | 481 crore, up 3.1% YoY, with margins at 19% Promoter 59.6 59.6 59.6 59.6 FII 23.7 24.2 24.0 25.0 Consequent PAT was at | 365 crore (down 5.3% YoY) DII 10.4 10.2 10.2 9.7 Others 6.3 6.0 6.2 5.7 What should investors do? Marico’s share price has given 84% return in the last five years (from | 297 in July 2016 to | 547 in July 2021).